BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study ...
Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome ...
A $4.7 million collaboration led by the National Cancer Centre Singapore will develop a clinical-grade test using AI and ...
Singapore Business Review on MSN
Lucence, DXD Hub, and NCCS launch $6m UNITED 2.0 cancer test
The team will adopt a dual WES-WTS approach for more detailed tumour profiling. Lucence, Diagnostics Development Hub hosted by A*STAR, and the National Cancer Centre Singapore have launched UNITED 2.0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results